Nuclear Medicine and Biology
Volume 34, Issue 8 , Pages 925-932 , November 2007

Preclinical evaluation of technetium 99m-labeled P1827DS for infection imaging and comparison with technetium 99m IL-8

  • Sabine Krause

      Affiliations

    • Bayer Schering Pharma AG, Global Drug Discovery, D-13342 Berlin, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 30 468 11476; fax: +49 30 468 91476.
    • ,
  • Huub J. Rennen

      Affiliations

    • Radboud University, Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    • ,
  • Otto C. Boerman

      Affiliations

    • Radboud University, Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    • ,
  • Sabine Baumann

      Affiliations

    • Bayer Schering Pharma AG, Global Drug Discovery, D-13342 Berlin, Germany
    • ,
  • John E. Cyr

      Affiliations

    • Bayer Schering Pharma AG, Global Drug Discovery, D-13342 Berlin, Germany
    • ,
  • Rajesh Manchanda

      Affiliations

    • Bayer Schering Pharma AG, Global Drug Discovery, D-13342 Berlin, Germany
    • Avid Radiopharmaceuticals, Philadelphia, PA, USA.
    • ,
  • John Lister-James

      Affiliations

    • Bayer Schering Pharma AG, Global Drug Discovery, D-13342 Berlin, Germany
    • ,
  • Frans C. Corstens

      Affiliations

    • Radboud University, Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    • ,
  • Ludger M. Dinkelborg

      Affiliations

    • Bayer Schering Pharma AG, Global Drug Discovery, D-13342 Berlin, Germany

Received 16 January 2007 ,Revised 31 May 2007 ,Accepted 25 July 2007.

References 

  1. Corstens FH, van der Meer JW. Nuclear medicine's role in infection and inflammation. Lancet. 1999;354:765–770
  2. Weiner RE, Thakur ML. Imaging infection/inflammations: pathophysiologic basis and radiopharmaceuticals. Q J Nucl Med. 1999;43:2–8
  3. Signore A, Chianelli M, Bei R, Oyen WJ, Modesti A. Targeting cytokine/chemokine receptors: a challenge for molecular nuclear medicine. Eur J Nucl Med Mol Imaging. 2003;30:149–156
  4. van Eerd JE, Boerman OC, Corstens FH, Oyen WJ. Radiolabeled chemotactic cytokines: new agents for scintigraphic imaging of infection and inflammation. Q J Nucl Med. 2003;47:246–255
  5. Brandt E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000;177:204–216
  6. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolinl M. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci U S A. 1993;90(8):3574–3577
  7. Slungaard A. Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol. 2005;37(6):1162–1167
  8. Kasper B, Brandt E, Bulfone-Paus S, Petersen F. Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by src-kinases, whereas PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidylinositol 3-kinase. Blood. 2004;103:1602–1610
  9. Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem. 2003;278(8):6187–6193
  10. Nesmelova IV, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, et al. PF4 and IL8 CXC-chemokine heterodimer formation modulates function at the quaternary structural level. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005;280(6):4948–4958
  11. Moyer BR, Vallabhajosula S, Lister-James J, Bush LR, Cyr JE, Snow DA, et al. Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J Nucl Med. 1996;37:673–679
  12. Palestro CJ, Weiland FL, Seabold JE, Valdiva S, Tomas MB, Moyer BR, et al. Localizing infection with technetium-99m-labeled peptide: initial results. Nucl Med Commun. 2001;22:695–701
  13. Patel L, Charlton SJ, Chambers JK, et al. Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine. 2001;14:27–36
  14. Holmes WE, Lee J, Kuang WJ, et al. Structure and functional expression of a human interleukin-8 receptor. Science. 1991;253:1278–1280
  15. Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science. 1991;253:1280–1283
  16. Lee J, Horuk R, Rice GC, et al. Characterization of two high affinity human interleukin-8 receptors. J Biol Chem. 1992;267:16283–16287
  17. Cerretti DP, Kozlosky CJ, Vanden Bos T, et al. Molecular characterization of receptors for human interleukin-8, GRO/melanoma growth-stimulatory activity and neutrophil activating peptide-2. Mol Immunol. 1993;30:359–367
  18. Rennen HJ, Boerman OC, Oyen WJ, et al. Specific and rapid scintigraphic detection of infection with 99mTc-labeled interleukin-8. J Nucl Med. 2001;42:117–123
  19. Gratz S, Rennen HJ, Boerman OC, et al. Rapid imaging of experimental colitis with 99mTc-interleukin-8 in rabbits. J Nucl Med. 2001;42:917–923
  20. Gratz S, Rennen HJ, Boerman OC, et al. (99m)Tc-interleukin-8 for imaging acute osteomyelitis. J Nucl Med. 2001;42:1257–1264
  21. Rennen HJ, Boerman OC, Oyen WJ, et al. Kinetics of 99mTc-labeled interleukin-8 in experimental inflammation and infection. J Nucl Med. 2003;44:1502–1509
  22. Rennen HJ, Bleeker C, Rovers P, vanEerd JE, Frielink C, Oyen WJ, et al. 99mTc-labeled interleukin-8 for scintigraphic detection of pulmonary infections. Chest. 2004;126(6):1954–1961
  23. Merrifield RB. Solid-phase synthesis of peptides. J Am Chem Soc. 1963;85:2149–2153
  24. Rennen HJ, Frielink C, Brandt E, Zaat SA, Boerman OC, Oyen WJ, et al. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms. J Nucl Med. 2004;45(7):1217–1223

PII: S0969-8051(07)00216-8

doi: 10.1016/j.nucmedbio.2007.07.016

Nuclear Medicine and Biology
Volume 34, Issue 8 , Pages 925-932 , November 2007

Article Tools

* Image Usage & Resolution